Assessment of Geriatric Evaluations Impact on New AML Guidance

Last updated: August 6, 2025
Sponsor: Abramson Cancer Center at Penn Medicine
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05909501
UPCC 11423
  • Ages > 50
  • All Genders

Study Summary

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy

  • New diagnosis being considered for new line of treatment

  • Age ≥ 50 years.

  • Performance status 0,1, and 2

Exclusion

Exclusion Criteria:

  • Inability to understand or unable to sign a written informed consent

  • Unable to fill out questionnaires on their own and/or do not have someone to helpcomplete them

Study Design

Total Participants: 100
Study Start date:
October 25, 2023
Estimated Completion Date:
December 01, 2026

Connect with a study center

  • Abramson Cancer Center at University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.